NCT04793945

Excimer Light and Topical Steroid in Treatment of Alopecia Areata

Status unknown Phase 4 Last updated 11 March 2021

What this trial tests

Phase 4 trial testing topical steroid and 308nm-Excimer light therapy in Alopecia Areata in 30 participants. Status unknown.

Timeline

1 April 2021

Primary endpoint
1 April 2022

30 September 2022

Quick facts

Lead sponsor	Assiut University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 April 2021
Primary completion	1 April 2022
Estimated completion	30 September 2022

Drugs / interventions tested

• topical steroid and 308nm-Excimer light therapy

Conditions studied

• Alopecia Areata — all drugs for Alopecia Areata →

Sponsor

Assiut University

Who can join

Adults 16 to 40, any sex, with Alopecia Areata. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Alopecia areata is a polygenic autoimmune disease causing hair loss, particularly during the anagen phase of hair growth This condition has a lifetime risk of about 2.1% of the world population and the cumulative incidence seems to rise linearly with age .

Patchy non scarring hair loss on the scalp is the most common clinical presentation, although it can also occur elsewhere . In addition to patchy Alopecia Areata , a more severe form, alopecia totalis , presents with diffuse hair loss across the scalp. In the most severe form, alopecia universalis , hair loss occurs on all areas of the body, including the beard, eyelashes, and extremities .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Treatments for alopecia areata: a network meta-analysis.
   Mateos-Haro M, Novoa-Candia M, Sánchez Vanegas G, Correa-Pérez A, et al · · 2023 · cited 16× · PMID 37870096 · DOI 10.1002/14651858.cd013719.pub2